-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis to present Phase 1 BALLI-01 lasme-cel data at EHA 2026

PUBT·05/12/2026 13:30:45
Listen to the news
Cellectis to present Phase 1 BALLI-01 lasme-cel data at EHA 2026
  • Cellectis flagged new clinical readouts for two allogeneic CAR-T programs scheduled for presentation at European Hematology Association congress in Stockholm on June 11-14, 2026; results will be presented in the future.
  • Phase 1 BALLI-01 dataset for lasme-cel in relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia is set for an oral presentation, with management pointing to a favorable safety profile and encouraging responses in heavily pretreated patients.
  • Those Phase 1 findings underpin a pivotal Phase 2 program now recruiting in Europe and North America, with interim data expected in Q4 2026.
  • Phase 1 NATHALI-01 poster for eti-cel in relapsed or refractory B-cell non-Hodgkin lymphoma will present an early analysis linking lymphodepletion exposure to cell expansion, immune signaling, and clinical outcomes, aimed at refining the regimen.
  • Full Phase 1 data from NATHALI-01 are planned for disclosure in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930OMX_____CNEWS_EN_GNW9718286_en) on May 12, 2026, and is solely responsible for the information contained therein.